Corcept Therapeutics Toekomstige groei
Future criteriumcontroles 6/6
Corcept Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 48.7% en 21.7% per jaar. De winst per aandeel zal naar verwachting groeien met 49.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 31.5% zijn.
Belangrijke informatie
48.7%
Groei van de winst
49.62%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 14.4% |
| Inkomstengroei | 21.7% |
| Toekomstig rendement op eigen vermogen | 31.46% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 13 May 2026 |
Recente toekomstige groei-updates
Recent updates
CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside
Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
Summary Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint. CORT 2026 revenue guidance was raised to $950–$1,050 million, driven by strong Lyforli uptake and robust Korlym sales, though risks include EU approval uncertainty and potential pricing pressures. Read the full article on Seeking AlphaCORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback
Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds
Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk
Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.CORT: Future Generic Ruling And Oncology Data Will Drive Upside
Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside
Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside
Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside
Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside
Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%
Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks
Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,550 | 534 | 225 | 490 | 5 |
| 12/31/2027 | 1,290 | 253 | 132 | 302 | 5 |
| 12/31/2026 | 989 | 84 | 108 | 150 | 5 |
| 3/31/2026 | 769 | 47 | 120 | 120 | N/A |
| 12/31/2025 | 761 | 98 | 142 | 142 | N/A |
| 9/30/2025 | 741 | 105 | 163 | 163 | N/A |
| 6/30/2025 | 716 | 132 | 180 | 182 | N/A |
| 3/31/2025 | 685 | 133 | 177 | 179 | N/A |
| 12/31/2024 | 675 | 140 | 196 | 198 | N/A |
| 9/30/2024 | 629 | 140 | 142 | 144 | N/A |
| 6/30/2024 | 570 | 125 | 123 | 124 | N/A |
| 3/31/2024 | 524 | 117 | 125 | 125 | N/A |
| 12/31/2023 | 482 | 105 | 127 | 127 | N/A |
| 9/30/2023 | 450 | 91 | 154 | 155 | N/A |
| 6/30/2023 | 428 | 94 | 135 | 135 | N/A |
| 3/31/2023 | 414 | 94 | 111 | 111 | N/A |
| 12/31/2022 | 402 | 101 | 120 | 120 | N/A |
| 9/30/2022 | 398 | 117 | 136 | 136 | N/A |
| 6/30/2022 | 392 | 113 | 151 | 151 | N/A |
| 3/31/2022 | 380 | 112 | 177 | 178 | N/A |
| 12/31/2021 | 366 | 113 | 167 | 168 | N/A |
| 9/30/2021 | 353 | 106 | 153 | 154 | N/A |
| 6/30/2021 | 343 | 98 | 134 | 135 | N/A |
| 3/31/2021 | 340 | 99 | 143 | 144 | N/A |
| 12/31/2020 | 354 | 106 | 151 | 152 | N/A |
| 9/30/2020 | 356 | 109 | 164 | 165 | N/A |
| 6/30/2020 | 351 | 114 | 173 | 173 | N/A |
| 3/31/2020 | 335 | 106 | 145 | 146 | N/A |
| 12/31/2019 | 306 | 94 | N/A | 136 | N/A |
| 9/30/2019 | 285 | 87 | N/A | 109 | N/A |
| 6/30/2019 | 268 | 78 | N/A | 115 | N/A |
| 3/31/2019 | 258 | 76 | N/A | 105 | N/A |
| 12/31/2018 | 251 | 75 | N/A | 116 | N/A |
| 9/30/2018 | 238 | 152 | N/A | 119 | N/A |
| 6/30/2018 | 216 | 148 | N/A | 85 | N/A |
| 3/31/2018 | 189 | 142 | N/A | 86 | N/A |
| 12/31/2017 | 159 | 129 | N/A | 61 | N/A |
| 9/30/2017 | 130 | 35 | N/A | 41 | N/A |
| 6/30/2017 | 109 | 24 | N/A | 39 | N/A |
| 3/31/2017 | 93 | 13 | N/A | 25 | N/A |
| 12/31/2016 | 81 | 8 | N/A | 18 | N/A |
| 9/30/2016 | 72 | 5 | N/A | 18 | N/A |
| 6/30/2016 | 64 | 1 | N/A | 10 | N/A |
| 3/31/2016 | 56 | -2 | N/A | 8 | N/A |
| 12/31/2015 | 50 | -6 | N/A | 3 | N/A |
| 9/30/2015 | 44 | -11 | N/A | -2 | N/A |
| 6/30/2015 | 38 | -17 | N/A | -9 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei CORT ( 48.7% per jaar) ligt boven de spaarquote ( 3.5% ).
Winst versus markt: De winst van CORT ( 48.7% per jaar) zal naar verwachting sneller groeien dan de US markt ( 16.8% per jaar).
Hoge groeiwinsten: De winst van CORT zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van CORT ( 21.7% per jaar) zal naar verwachting sneller groeien dan de markt US ( 11.6% per jaar).
Hoge groei-inkomsten: De omzet van CORT ( 21.7% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen CORT zal naar verwachting over 3 jaar hoog zijn ( 31.5 %)
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/20 06:15 |
| Aandelenkoers aan het einde van de dag | 2026/05/20 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Corcept Therapeutics Incorporated wordt gevolgd door 18 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |